Loading clinical trials...

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

NCT05823740•UNC Lineberger Comprehensive Cancer Center

View on ClinicalTrials.gov

Summary

The primary objective of this study is to evaluate the feasibility and acceptability of obtaining repeated measurements of lean muscle mass, physical function, and biological aging in children receiving active cancer therapy. The secondary objective is to evaluate the feasibility of using the D3-creatine dilution method (D3Cr) to measure skeletal muscle mass in children with cancer. Assessments will be collected at diagnosis, once during active treatment, and end of treatment in coordination with routine imaging to monitor changes in study outcomes during active cancer treatment. Key sociodemographic, treatment and health-related factors will be abstracted from the medical record.

Eligibility

Age

8 - 21 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Ages 8-21 years at the time of cancer diagnosis
•2. Must have a newly diagnosed malignant solid tumor or lymphoma.
•3. Participant is expected to undergo cancer treatment with either chemotherapy, radiation, immunotherapy, or other biologically targeted therapy.
•4. Participants will undergo routine imaging with either computed tomography (CT), or Magnetic Resonance Imaging (MRI) of the chest or abdomen, or whole-body positron emission tomography (PET) scan.
•5. Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information.
•6. English or Spanish speaking
•7. Subject is willing and able to comply with study procedures.
•8. Since the patient is undergoing active cancer therapy, must obtain approval from the treating physician.

Exclusion Criteria

•1. Prior history of cancer
•2. Treatment with surgical excision alone
•3. Planned palliative treatment.
•4. Subject has elected to forgo chemotherapy or radiotherapy.
•5. Any diagnosis of leukemia.
•6. Clinical concerns that the treating clinician feels would preclude participation in the study.
•7. Subject has a pacemaker or bilateral joint prosthesis that would prevent undergoing BIA assessment.
•8. Unwilling to sign informed consent.
•9. Speak a language other than English or Spanish.

Locations (1)

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

Key Dates

Start Date

May 1, 2023

Primary Completion Date

March 31, 2026

Completion Date

March 31, 2026

Last Updated

February 20, 2026

Enrollment

ACTUAL participants

Conditions

CancerMalignant Neoplasm

Interventions

Bioelectrical impedance Analysis (BIA)

OTHER

D3-Creatine Dilution (D3Cr)

OTHER

6-Minute Walk Test (6MWT)

OTHER

Timed Up and Go (TUG)

OTHER

30-second Sit-to-Stand (STS)

OTHER

Hand Grip Strength (GS)

OTHER

PBTL p16 expression

OTHER

CT, MR and PET Imaging

OTHER

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma